Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Phillips Molluscum Treatment System is a medical device-based therapy developed by ReBuilder Medical Technologies for the treatment of Molluscum Contagiosum, a viral skin infection common in children. The system utilizes nano-silver, specifically micronized amorphous silver ions, which act as an antimicrobial agent to disable the molluscum pathogen. This active ingredient is delivered to the skin lesions using a battery-powered electronic accelerator unit, providing a non-invasive and painless alternative to traditional physical destruction methods like cryotherapy or curettage. The technology was originally developed by Molluscum Medical Technologies and licensed to ReBuilder Medical Technologies in 2007.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Phillips Molluscum Treatment System.